For most of the past two decades, Intuitive Surgical's da Vinci robotic surgery system was essentially synonymous with surgical robotics. The company held dominant market share, hospitals that invested in da Vinci systems were locked into its consumables and service contracts, and new entrants faced enormous barriers to clinical validation. That monopoly-adjacent position is now genuinely threatened for the first time, as a wave of new surgical robot companies has cleared regulatory hurdles and entered clinical practice.
Medtronic's Hugo RAS system received FDA clearance in 2023 and has been expanding its installed base across the US and Europe. Johnson & Johnson's Ottava platform is in clinical evaluation. CMR Surgical's Versius, which has a modular port-by-port architecture that makes it more flexible for different procedure types and operating room layouts, is approved and deployed in Europe and Asia, with US approval pending. Moon Surgical's Maestro system, which augments rather than replaces laparoscopic tools and costs a fraction of a full robotic platform, has found adoption in facilities that cannot justify the $1-2 million capital cost of a full system.
The competitive pressure is doing what competition typically does: driving down prices and expanding capability. Intuitive Surgical has responded with the da Vinci 5, its fifth-generation platform, which includes haptic feedback (surgeons can feel resistance through the instruments), improved 3D visualization, and reduced setup time. The da Vinci 5 also reduces the number of instrument exchanges per procedure, which is relevant because each da Vinci instrument is a single-use item at roughly $200-$700 per instrument — a significant ongoing cost that has drawn criticism from hospital administrators.
The clinical outcomes data for robotic surgery continues to accumulate. For prostatectomy, the evidence is strongest: robotic-assisted procedures show significantly lower rates of positive surgical margins and faster patient recovery compared to open surgery, with comparable oncological outcomes. For colorectal surgery, hysterectomy, and nephrectomy, robotic assistance shows benefits in blood loss and hospital length of stay, though not universally in long-term outcomes. The procedure types where robotic surgery is genuinely superior to skilled laparoscopic surgery remain narrower than the technology's marketing often implies.
The next frontier in surgical robotics is autonomy. Current systems are master-slave: the robot precisely replicates the surgeon's hand movements, scaling and filtering tremor, but makes no independent decisions. Researchers at Johns Hopkins, ETH Zurich, and several startups are working toward robots that can perform specific sub-tasks autonomously — suturing a defined path, dissecting along a tissue plane — while the surgeon maintains oversight. This is a research agenda for the late 2020s rather than an immediate commercial reality, but the trajectory is clear.